- FDA approves Otsuka and Lundbeck injection for schizophrenia and bipolar disorder – Endpoints NewsTerminal News
- FDA approves Otsuka and Lundbeck’s long-acting AbilifyFiercePharma
- FDA approves aripiprazole as first long-acting injectable once every 2 months for schizophrenia, bipolar I disorderPharmacy hours
- NDA Approved for Long-Acting Injectables for Schizophrenia and Bipolar IPsychiatric time
- FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the first long-acting injectable (LAI) once every two months for the treatment of schizophrenia or the maintenance monotherapy treatment of bipolar I disorder in ‘adultbusiness thread
- See full coverage on Google News